A lawsuit filed by a former executive of Juul claims they knowingly sold 1 million contaminated pods; Novartis trial for its Zolgensma gene therapy stopped amid safety concerns; charts show worsening air quality in Louisiana.
A lawsuit filed by a former executive of the e-cigarette manufacturer Juul Labs alleges the company knowingly shipped 1 million contaminated pods to retailers and refused to warn or recall the products, according to The Hill. Siddharth Breja, who was Juul’s senior vice president of global finance in 2018 and 2019, is suing the company for damages after he claims he was fired for being a whistleblower. The claims provide possible links to the rise in vaping-related lung illnesses occurring this year.Novartis AG halted its clinical STRONG trial of its Zolgensma gene therapy after a separate study on animals raised concerns of possible side effects, according to Reuters. The side effects potentially linked to the treatment, approved for pediatrics patients up to age 2, were reported by Novartis to health authorities, which included dorsal root ganglia mononuclear cell inflammation, a neurological condition that can be accompanied by nerve damage or loss. The announcement serves as a setback for the drugmaker, which was to test the treatment, at a higher dose, in children up to age 5 with spinal muscular atrophy.In a report published by ProPublica, 3 charts showed the growing effect of the chemical industry on worsening conditions of air quality in Louisiana. The growth of the chemical industry in Louisiana is especially concerning as toxic levels of cancer-causing chemicals in the air continues to grow. One region in particular, nicknamed "Cancer Alley," has recently been approved by Louisiana for build new chemical plants in an already toxic area. Air quality has been improving in the United States, but progress in Louisiana has stalled.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More